Marina Konopleva, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results from a comparison of 10-day decitabine plus venetoclax therapy (DEC10-VEN) and intensive chemotherapy (IC) in relapsed/refractory acute myeloid leukemia (AML), a cohort lacking standard approved treatments. A propensity score-matched analysis (PSMA) analysis was conducted to match DEC10-VEN patients with IC patients, based on age, ELN risk group, ECOG performance status, and number of prior therapies. The results show DEC10-VEN has efficacy as salvage therapy, comparable to intensive chemotherapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.